Early results from a double-blind, randomized phase IIB trial of difluoromethylorthine plus sulindac for colon cancer prevention.

被引：0
|
作者：
Meyskens, FL
Pelot, D
MacLaren, CE
Lagerberg, W
Li, KT
Carpenter, P
Gerner, E
Goldschmid, S
Kidao, J
Ahnen, D
Lawson, MJ
McCracken, J
机构：
[1] Chao Family Comprehens Canc Ctr, Orange, CA USA
[2] Univ Calif Irvine, Irvine, CA USA
[3] Arizona Canc Ctr, Tucson, AZ USA
[4] Long Beach VA Med Ctr, Long Beach, CA USA
[5] Univ Colorado, Sch Med, Denver, CO USA
[6] Kaiser Permanente, Sacramento, CA USA
[7] Loma Linda Univ, Loma Linda, CA 92350 USA
[8] Pettis VA Med Ctr, Loma Linda, CA USA
来源：
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION | 2004年 / 13卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1904S / 1904S
页数：1
相关论文
共 50 条
  • [1] Toxicity to participants on a double-blind, randomized phase IIB trial of difluoromethylornithine plus sulindac is equivalent in the treatment and placebo arms.
    Pelot, D
    Li, KT
    Lagerberg, W
    McLaren, C
    Carpenter, P
    Gerner, E
    Goldschmid, S
    Kidao, J
    Ahnen, D
    Lawson, M
    McCracken, J
    Meyskens, F
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2002, 11 (10) : 1193S - 1193S
  • [2] Toxicity to participants an a double-blind, randomized phase IIB trial of difluoromethyornithine plus sulindac is equivalent in the treatment and placebo arms.
    Pelot, D
    Li, KT
    Lagerberg, W
    McLaren, C
    Meyskens, F
    Gerner, E
    GASTROENTEROLOGY, 2002, 122 (04) : A215 - A215
  • [3] Preliminary results of a randomized phase IIb double-blind 2x2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention.
    Bonanni, B
    Guerrieri-Gonzaga, A
    Robertson, C
    Serrano, D
    Cazzaniga, M
    Mora, S
    Gulisano, M
    Johansson, H
    Galimberti, V
    Intra, M
    Latronico, A
    Franchi, D
    Pelosi, D
    Decensi, A
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S168 - S169
  • [4] Tocilizumab in Myositis: Results of a Phase IIb Double-Blind Randomized Controlled Trial
    Aggarwal, Rohit
    Rockette, Howard
    Venturupalli, Swamy
    Marder, Galina
    Dimachkie, Mazen
    Gazeley, David
    Ernste, Floranne C.
    Crofford, Leslie
    Moghadam-Kia, Siamak
    Koontz, Diane
    Zhu, Lei
    Oddis, Chester
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [5] Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial
    Meyskens, Frank L., Jr.
    McLaren, Christine E.
    Pelot, Daniel
    Fujikawa-Brooks, Sharon
    Carpenter, Philip M.
    Hawk, Ernest
    Kelloff, Gary
    Lawson, Michael J.
    Kidao, Jayashri
    McCracken, John
    Albers, C. Gregory
    Ahnen, Dennis J.
    Turgeon, D. Kim
    Goldschmid, Steven
    Lance, Peter
    Hagedorn, Curt H.
    Gillen, Daniel L.
    Gerner, Eugene W.
    CANCER PREVENTION RESEARCH, 2008, 1 (01) : 32 - 38
  • [6] Role of obesity in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas.
    Lin, B. S.
    Zell, J. A.
    Madson, N.
    McLaren, C. E.
    Gerner, E. W.
    Meyskens, F. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [7] Risk of Cardiovascular Events in a Randomized Placebo-Controlled, Double-Blind Trial of Difluoromethylornithine plus Sulindac for the Prevention of Sporadic Colorectal Adenomas
    Zell, Jason A.
    Pelot, Daniel
    Chen, Wen-Pin
    McLaren, Christine E.
    Gerner, Eugene W.
    Meyskens, Andfrank L.
    CANCER PREVENTION RESEARCH, 2009, 2 (03) : 209 - 212
  • [8] Influence of modafinil on early ejaculation - Results from a double-blind randomized clinical trial
    Haghighi, Mohammad
    Jahangard, Leila
    Meybodi, Azadeh Mazahri
    Shayganfard, Mehran
    Ahmadpanah, Mohammad
    Faryadres, Mohammad
    Dursteler, Kenneth M.
    Bruhl, Annette Beatrix
    Sadeghi-Bahmani, Dena
    Brand, Serge
    JOURNAL OF PSYCHIATRIC RESEARCH, 2022, 146 : 264 - 271
  • [9] Trial of retinol and isotretinoin in skin cancer prevention: A randomized, double-blind, controlled trial
    Levine, N
    Moon, TE
    Cartmel, B
    Bangert, JL
    Rodney, S
    Dong, Q
    Peng, YM
    Alberts, DS
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 1997, 6 (11) : 957 - 961
  • [10] A Randomized Double-Blind Placebo-Controlled Phase IIB Trial of Curcumin in Oral Leukoplakia
    Kuriakose, Moni Abraham
    Ramdas, Kunnambath
    Dey, Bindu
    Iyer, Subramanya
    Rajan, Gunaseelan
    Elango, Kalavathy K.
    Suresh, Amritha
    Ravindran, Divya
    Kumar, Rajneesh R.
    Prathiba, R.
    Ramachandran, Surya
    Kumar, Nisha Asok
    Thomas, Gigi
    Somanathan, Thara
    Ravindran, Hiran K.
    Ranganathan, Kannan
    Katakam, Sudhakar Babu
    Parashuram, Shivashankar
    Jayaprakash, Vijayvel
    Pillai, M. Radhakrishna
    CANCER PREVENTION RESEARCH, 2016, 9 (08) : 683 - 691
12345